PL375064A1 - Leczenie raka nerki przy użyciu przeciwciał skierowanych przeciwko EGFr - Google Patents

Leczenie raka nerki przy użyciu przeciwciał skierowanych przeciwko EGFr

Info

Publication number
PL375064A1
PL375064A1 PL03375064A PL37506403A PL375064A1 PL 375064 A1 PL375064 A1 PL 375064A1 PL 03375064 A PL03375064 A PL 03375064A PL 37506403 A PL37506403 A PL 37506403A PL 375064 A1 PL375064 A1 PL 375064A1
Authority
PL
Poland
Prior art keywords
egfr
treatment
antibodies against
renal carcinoma
carcinoma
Prior art date
Application number
PL03375064A
Other languages
English (en)
Inventor
Gisela Schwab
Xiao-Dong Yang
Original Assignee
Abgenix, Inc.
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenix, Inc., Immunex Corporation filed Critical Abgenix, Inc.
Publication of PL375064A1 publication Critical patent/PL375064A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL03375064A 2002-05-20 2003-05-19 Leczenie raka nerki przy użyciu przeciwciał skierowanych przeciwko EGFr PL375064A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38215202P 2002-05-20 2002-05-20

Publications (1)

Publication Number Publication Date
PL375064A1 true PL375064A1 (pl) 2005-11-14

Family

ID=29584366

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03375064A PL375064A1 (pl) 2002-05-20 2003-05-19 Leczenie raka nerki przy użyciu przeciwciał skierowanych przeciwko EGFr

Country Status (8)

Country Link
US (1) US20040033543A1 (pl)
EP (1) EP1575491A4 (pl)
JP (1) JP2006508899A (pl)
AU (1) AU2003239505A1 (pl)
CA (1) CA2485691A1 (pl)
MX (1) MXPA04011550A (pl)
PL (1) PL375064A1 (pl)
WO (1) WO2003099205A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
JP5554925B2 (ja) 2006-01-20 2014-07-23 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
PL2412828T3 (pl) 2007-03-13 2013-11-29 Amgen Inc Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr
US20080293055A1 (en) 2007-03-13 2008-11-27 Daniel Freeman K-ras mutations and anti-EGFr antibody therapy
JP5618549B2 (ja) * 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
EP3072963B1 (en) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
MX2011001927A (es) 2008-08-29 2011-04-21 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
SI2881402T1 (sl) 2009-02-12 2017-12-29 Cell Signaling Technology, Inc. Ekspresija mutantnega ros pri humanem raku jeter
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
MX351251B (es) 2011-09-09 2017-10-06 Amgen Inc Uso del estado del virus del papiloma humano en establecer el uso de un agente que enlaza el receptor del factor de crecimiento anti-epidermal en el tratamiento de cáncer.
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
US9717792B2 (en) * 2012-02-02 2017-08-01 The University Of British Columbia Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates
WO2013158859A1 (en) 2012-04-18 2013-10-24 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
US9565773B2 (en) * 2014-03-31 2017-02-07 Apple Inc. Methods for assembling electronic devices with adhesive
WO2017049272A1 (en) * 2015-09-17 2017-03-23 Research Foundation Of The City University Of New York Method for mitigating metastasis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU658396B2 (en) * 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
EP1972194A1 (en) * 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
EP1575491A2 (en) 2005-09-21
EP1575491A4 (en) 2006-09-27
JP2006508899A (ja) 2006-03-16
WO2003099205A2 (en) 2003-12-04
US20040033543A1 (en) 2004-02-19
WO2003099205A3 (en) 2005-12-22
CA2485691A1 (en) 2003-12-04
AU2003239505A1 (en) 2003-12-12
MXPA04011550A (es) 2005-02-17

Similar Documents

Publication Publication Date Title
EP1575491A4 (en) TREATMENT OF RENAL CARCINOMA USING ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR
EP1572131A4 (en) ANTIBODY THERAPY
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
IL166244A0 (en) Super humanized antibodies
PL375405A1 (pl) Przeciwciała
IL246594A0 (en) Treatment with anti-vegf antibodies
EP1432444A4 (en) ANTI-BETA ANTIBODIES
IL175935A0 (en) Solid forms of anti-egfr antibodies
PL371486A1 (pl) Związki chinazolinowe
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
IL173557A0 (en) Variable antibodies
AUPR395801A0 (en) Antibodies against cancer
AU2003212634A8 (en) Compounds useful in the treatment of cancer
PL377464A1 (pl) Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN
AU2002351374A8 (en) Antibodies to treat cancer
EP1549343A4 (en) PROCESS FOR TREATING NEPHRITIS WITH ANTI-PDGF-DD ANTIBODIES
AU2003277832A8 (en) Humanized tissue factor antibodies
AU2003302822A8 (en) Antibodies to treat cancer
GB2389532C (en) The method of treating cancer
GB0226595D0 (en) Cancer therapy determination
GB0226878D0 (en) Antibodies
HK1076746A (en) Treatment of renal carcinoma using antibodies against the egfr
EP1446416A4 (en) TUMOR-SPECIFIC MONOCLONAL ANTIBODIES
GB0223325D0 (en) Treating cancer
GB2383538B (en) Cancer treatment

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)